Technical Analysis for URGN - UroGen Pharma Ltd.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 20 DMA | Bearish | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Weak + Overbought | Other | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Crossed Above 20 DMA | Bullish | -1.85% | |
Bollinger Band Squeeze | Range Contraction | -1.85% | |
Stochastic Reached Overbought | Strength | -1.85% | |
Weak + Overbought | Other | -1.85% | |
BB Squeeze Started | Range Contraction | -1.85% |
Alert | Time |
---|---|
Possible Inside Day | 1 day ago |
20 DMA Support | 1 day ago |
10 DMA Support | 1 day ago |
Down 2 % | 1 day ago |
Fell Below 20 DMA | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 05/13/2024
UroGen Pharma Ltd. Description
UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunotherapy Surgery Chemotherapy Antineoplastic Drugs Carcinoma Bladder Cancer Platform Technologies Botulinum Toxin Oab Interstitial Cystitis Overactive Bladder Tlr7 Two Platform Technologies Urinary Bladder
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 24.13 |
52 Week Low | 8.69 |
Average Volume | 346,012 |
200-Day Moving Average | 14.85 |
50-Day Moving Average | 13.90 |
20-Day Moving Average | 13.31 |
10-Day Moving Average | 13.25 |
Average True Range | 0.76 |
RSI (14) | 47.09 |
ADX | 22.05 |
+DI | 15.59 |
-DI | 21.36 |
Chandelier Exit (Long, 3 ATRs) | 12.61 |
Chandelier Exit (Short, 3 ATRs) | 12.88 |
Upper Bollinger Bands | 14.04 |
Lower Bollinger Band | 12.58 |
Percent B (%b) | 0.5 |
BandWidth | 10.99 |
MACD Line | -0.20 |
MACD Signal Line | -0.28 |
MACD Histogram | 0.0787 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 14.20 | ||||
Resistance 3 (R3) | 14.28 | 14.06 | 14.05 | ||
Resistance 2 (R2) | 14.06 | 13.83 | 14.02 | 14.00 | |
Resistance 1 (R1) | 13.68 | 13.69 | 13.57 | 13.60 | 13.95 |
Pivot Point | 13.46 | 13.46 | 13.41 | 13.42 | 13.46 |
Support 1 (S1) | 13.08 | 13.23 | 12.97 | 13.00 | 12.65 |
Support 2 (S2) | 12.86 | 13.09 | 12.82 | 12.60 | |
Support 3 (S3) | 12.48 | 12.86 | 12.55 | ||
Support 4 (S4) | 12.40 |